Jacobus Pharmaceutical Company Inc. is recalling 2,324 bottles of Ruzurgi (amifampridine) 10 mg tablets because company testing found levels of bacteria, yeast, and mold that exceed safety limits. Ruzurgi is a prescription medication used to treat a rare muscle disease called Lambert-Eaton Myasthenic Syndrome. No injuries or illnesses have been reported to date, but the company is taking this voluntary action as a precaution. Patients should contact their doctor or pharmacist to discuss their treatment options while this recall is underway.
Taking medication contaminated with bacteria, yeast, or mold can cause serious infections or other adverse health reactions, particularly in patients with weakened immune systems. No incidents have been reported, but the elevated microbial counts found during testing pose a potential safety risk to consumers.
You have 2 options:
Lot 18038 was distributed to Canada only.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.